Art. -Nr.: HY-12727

Copy Link Print Information

EPZ015666

(Synonyms: GSK3235025)

22 Cited Publications

Kundenbewertung

Based on 22 publication(s) in Google Scholar

EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC₅₀ of 22 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.86%
CAS. Nr.: 1616391-65-1
Formel: C₂₀H₂₅N₅O₃
Molecular Weight:383.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

EPZ015666 Chemical Structure

CAS. Nr.: 1616391-65-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (22)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC₅₀ of 22 nM.

IC₅₀ & Target

PRMT5

Alle Histone Methyltransferase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.32 μM Compound: EPZ015666	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 38518523]
HCC38	IC₅₀	5 μM Compound: 66; EPZ015666, GSK3235025	Anticancer activity against human HCC38 cells assessed as cell growth inhibition by MTT assay Anticancer activity against human HCC38 cells assessed as cell growth inhibition by MTT assay	[PMID: 33650861]
HeLa	IC₅₀	0.29 μM Compound: EPZ015666	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 38518523]
HepG2	IC₅₀	1.04 μM Compound: EPZ015666	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 38518523]
KARPAS-422	IC₅₀	0.96 μM Compound: 8; EPZ015666	Antiproliferative activity against human KARPAS422 cells after 4 days by cell titer-glo luminescent cell viability assay Antiproliferative activity against human KARPAS422 cells after 4 days by cell titer-glo luminescent cell viability assay	[PMID: 30366617]
Maver1	IC₅₀	450 nM Compound: 1	Antiproliferative activity against human Maver1 cells measured after 12 days post culturing by guava via count reagent assay Antiproliferative activity against human Maver1 cells measured after 12 days post culturing by guava via count reagent assay	[PMID: 29870258]
Maver1	IC₅₀	450 nM Compound: 21; EPZ015666	Antiproliferative activity against human MAVER-1 cells assessed as cell growth inhibition incubated for 12 days by Guava ViaCount Reagent Assay Antiproliferative activity against human MAVER-1 cells assessed as cell growth inhibition incubated for 12 days by Guava ViaCount Reagent Assay	[PMID: 37366223]
MCF7	IC₅₀	0.74 μM Compound: EPZ015666	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 38518523]
MDA-MB-231	IC₅₀	0.43 μM Compound: EPZ015666	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 38518523]
MDA-MB-231	IC₅₀	60 μM Compound: 66; EPZ015666, GSK3235025	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 33650861]
MDA-MB-468	IC₅₀	1 μM Compound: 66; EPZ015666, GSK3235025	Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition by MTT assay Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition by MTT assay	[PMID: 33650861]
MV4-11	GI₅₀	0.106 μM Compound: 1; EPZ015666	Antiproliferative activity against human MV4-11 cells supplemented with fresh medium containing compound every 4 days measured on day 12 by Celltiter-glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells supplemented with fresh medium containing compound every 4 days measured on day 12 by Celltiter-glo luminescent cell viability assay	[PMID: 30605830]
MV4-11	GI₅₀	0.212 μM Compound: 1; EPZ015666	Antiproliferative activity against human MV4-11 cells supplemented with fresh medium containing compound every 4 days measured on day 8 by Celltiter-glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells supplemented with fresh medium containing compound every 4 days measured on day 8 by Celltiter-glo luminescent cell viability assay	[PMID: 30605830]
MV4-11	IC₅₀	1.8 μM Compound: 8; EPZ015666	Antiproliferative activity against human MV4-11 cells after 4 days by cell titer-glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells after 4 days by cell titer-glo luminescent cell viability assay	[PMID: 30366617]
Pfeiffer	IC₅₀	1.1 μM Compound: 8; EPZ015666	Antiproliferative activity against human Pfeiffer cells after 4 days by cell titer-glo luminescent cell viability assay Antiproliferative activity against human Pfeiffer cells after 4 days by cell titer-glo luminescent cell viability assay	[PMID: 30366617]
SUD4	IC₅₀	2.6 μM Compound: 8; EPZ015666	Antiproliferative activity against human SU-DHL4 cells after 4 days by cell titer-glo luminescent cell viability assay Antiproliferative activity against human SU-DHL4 cells after 4 days by cell titer-glo luminescent cell viability assay	[PMID: 30366617]
Z-138	IC₅₀	351 nM Compound: EPZ015666; GSK3235025	Antiproliferative activity against human Z138 cells incubated for 5 days by cell titer-glo assay Antiproliferative activity against human Z138 cells incubated for 5 days by cell titer-glo assay	[PMID: 26985292]
Z-138	IC₅₀	450 nM Compound: 21; EPZ015666	Antiproliferative activity against human Z138 cells assessed as cell growth inhibition incubated for 12 days by Guava ViaCount Reagent Assay Antiproliferative activity against human Z138 cells assessed as cell growth inhibition incubated for 12 days by Guava ViaCount Reagent Assay	[PMID: 37366223]
Z-138	IC₅₀	96 nM Compound: 1	Antiproliferative activity against human Z138 cells measured after 12 days post culturing by guava via count reagent assay Antiproliferative activity against human Z138 cells measured after 12 days post culturing by guava via count reagent assay	[PMID: 29870258]

In Vitro

Treatment of MCL cell lines with EPZ015666 (GSK3235025) leads to inhibition of SmD3 methylation and cell death, with IC₅₀ values in the nanomolar range^[1]. EPZ015666 (GSK3235025), a potent peptide-competitive and SAM-cooperative inhibitor with >10,000-fold specificity against PRMT5 relative to other methyltransferases^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

EPZ015666 (GSK3235025) is orally bioavailable and amenable to in vivo studies. We performed 21-d efficacy studies in severe combined immunodeficiency (SCID) mice bearing subcutaneous Z-138 and Maver-1 xenografts, with twice-daily (BID) oral dosing on four dose groups: 25, 50, 100 and 200 mg per kilogram of body weight (mg/kg). After 21 d of continuous dosing, animals are euthanized, and blood and tissues are analyzed to determine the relationship between methyl-mark pharmacodynamics and tumor-growth inhibition (TGI). EPZ015666 (GSK3235025) showed dose-dependent exposure and TGI after 21 d in both MCL models. Tumors in all EPZ015666 (GSK3235025) dose groups measured on day 21 showed statistically significant differences in weight, volume and tumor growth compared to vehicle-treated tumors. Dosing at 200 mg/kg BID induced tumor stasis in Z-138 cells, with >93% TGI after 21 d, whereas Maver-1 cells showed >70% TGI. Additionally, a third MCL xenograft is tested using the Granta-519 cell line, a fast-growing model that reached endpoint on day 18 and showed dose-dependent efficacy with 45% TGI in the 200 mg/kg group. EPZ015666 (GSK3235025) is well tolerated in all three models, with minimal bodyweight loss in the 200 mg/kg dose group and no other clinical observations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1616391-65-1
Appearance Solid
Molecular Weight 383.44
Formel C₂₀H₂₅N₅O₃
Color White to off-white
SMILES

O=C(NC[C@H](O)CN1CCC(C=CC=C2)=C2C1)C3=CC(NC4COC4)=NC=N3
Synonyms

GSK3235025
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (22)

All 2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayHistological Imaging/StainingOthersWB

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Adv Sci (Weinh)

PRMT5 Maintains Homeostasis of the Intestinal Epithelium by Modulating Cell Proliferation and Survival. [Abstract]

2025 Feb 3:e2415559. PMID: 39899687

EPZ015666 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2415559. [Abstract]

EPZ015666 (2.5 μM). After treating the compound for 4 or 5 days, the number of shoots or surviving organoids was observed and quantified.

EPZ015666 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2415559. [Abstract]

Indicated proteins were detected by immunoblotting in small intestinal organoids treated with vehicle (DMSO), EPZ015666 or LLY283 for 3 days.
J Exp Clin Cancer Res

A novel polypeptide encoded by circSPIRE1 promotes prostate cancer proliferation and migration by restraining the ubiquitin-dependent degradation of LRP5. [Abstract]

2025 Jul 25;44(1):218. PMID: 40713830

EPZ015666 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 25;44(1):218. [Abstract]

The DMA inhibitor EPZ015666 (10 µM) reduced the activity of Fluc in circSPIRE1 IRES transfected cells, but had no effect on Rluc.
J Exp Clin Cancer Res

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]

2023 Aug 21;42(1):214. PMID: 37599362
J Exp Clin Cancer Res

Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. [Abstract]

2022 Oct 5;41(1):293. PMID: 36199122
J Exp Clin Cancer Res

The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression. [Abstract]

2022 Jun 2;41(1):191. PMID: 35655230

EPZ015666 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Jun 2;41(1):191. [Abstract]

Changes in cell viability after treatment with 40 μM FKA, two PRMT5 inhibitors EPZ015666 (22 nM), and the first-line chemotherapy drug BC. Combined treatment with FKA or PRMT5 inhibitors and GC showed a synergistic effect on cell viability of T24 cells (left panel) and UMUC3 cells (right panel).
Sci Adv

A PRMT5-ZNF326 axis mediates innate immune activation upon replication stress. [Abstract]

2024 Jun 7;10(23):eadm9589. PMID: 38838142

EPZ015666 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Jun 7;10(23):eadm9589. [Abstract]

CXCL10-HiBiT expression from CXCL10-HiBiT knock-in MCF10A cells treated with DMSO, HU (1 mM), HU (1 mM) + GSK591 (1 μM), and HU (1 mM) + EPZ015666 (1 μM) for 48 hours.
Cancer Lett

Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. [Abstract]

2024 Aug 30:217214. PMID: 39218291
Cell Commun Signal

Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML. [Abstract]

2025 Mar 8;23(1):126. PMID: 40057764
Acta Pharmacol Sin

Adriamycin induces cardiac fibrosis in mice via PRMT5-mediated cardiac fibroblast activation. [Abstract]

2023 Mar;44(3):573-583. PMID: 36056082
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
J Mol Cell Biol

Methylation of MATCAP by PRMT5 regulates microtubule detyrosination to ensure mitotic fidelity. [Abstract]

2026 Mar 11:mjag008. PMID: 41811993
J Biol Chem

Prmt5 promotes ciliated cell specification of airway epithelial progenitors via transcriptional inhibition of Tp63. [Abstract]

2023 Aug;299(8):104964. PMID: 37364687
J Biol Chem

Protein arginine methyltransferase 5 is essential for oncogene product EWSR1-ATF1-mediated gene transcription in clear cell sarcoma. [Abstract]

2022 Oct;298(10):102434. PMID: 36041632
J Biol Chem

Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins. [Abstract]

2022 Sep;298(9):102367. PMID: 35963436
J Proteome Res

ETD-Based Proteomic Profiling Improves Arginine Methylation Identification and Reveals Novel PRMT5 Substrates. [Abstract]

2024 Mar 1;23(3):1014-1027. PMID: 38272855
PLoS One

Asymmetric and symmetric protein arginine methylation in methionine-addicted human cancer cells. [Abstract]

2023 Dec 22;18(12):e0296291. PMID: 38134182
Biomed Res Int

Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4. [Abstract]

2021 Oct 19;2021:7329072. PMID: 34712735
Exp Ther Med

Protein arginine methyltransferase 5 mediates THP-1-derived macrophage activation dependent on NF-κB in endometriosis. [Abstract]

2021 Sep;22(3):1003. PMID: 34345285
bioRxiv

2026 Apr 13.
Research Square Print

2023 Feb.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (260.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6080 mL

13.0399 mL

26.0797 mL

5 mM

0.5216 mL

2.6080 mL

5.2159 mL

10 mM

0.2608 mL

1.3040 mL

2.6080 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Cultured cells in linear/log-phase growth are split to a seeding density of 2×10⁵ cells/mL in 2-20 mL of media, depending on the yield required at the end of the growth period. Compound is diluted in DMSO and added to each culture vessel with a final DMSO concentration of 0.2%. Cells are allowed to grow for 96 h undisturbed. At the conclusion of each treatment period, cells are harvested by centrifugation (5 min, 1,200 rpm), and cell pellets are rinsed once with PBS before being frozen on dry ice pending further processing. Long-term proliferation assays are performed on all MCL lines, with slight adjustments to initial seeding densities, depending on growth characteristics for each cell line. All assays are carried out for 12 d^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Male CD-1 mice (25-40 g; n=6, with 3 per time point) are treated with a single dose of EPZ015666 (GSK3235025) at 2 mg/kg by intravenous tail-vein injection and 10 mg/kg by oral gavage administration, with both doses formulated in 20% N-N-dimethylacetamide in water. Animals are fasted overnight and weighed before dose administration on the day of dosing. Approximately 30 μL of blood are taken from animals by submandibular or retro-orbital bleeding at pre-specified time intervals (seven time points). For the last time point (24 h), samples are collected via cardiac puncture while the animals are under anesthesia (70% CO₂:30% O₂). Blood samples are transferred into K₂-EDTA tubes and placed on wet ice before centrifugation at 4°C (3,000g, 15 min) to obtain plasma within 30 min after sample collection. Plasma samples are stored at −70±10°C before protein precipitation and LC-MS/MS analysis. We constructed standard calibration curves by analyzing a series of control plasma aliquots containing 100 ng/mL labetalol as an internal standard and 1-3,000 ng/mL EPZ015666 (GSK3235025). Four levels of quality control are also included in the analysis (3-2,400 ng/mL EPZ015666 (GSK3235025)). Data are analyzed using Phoenix WinNonlin 6.2.1.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chan-Penebre E, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. [Content Brief]

[2]. Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11;351(6278):1214-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6080 mL	13.0398 mL	26.0797 mL	65.1992 mL
	5 mM	0.5216 mL	2.6080 mL	5.2159 mL	13.0398 mL
	10 mM	0.2608 mL	1.3040 mL	2.6080 mL	6.5199 mL
	15 mM	0.1739 mL	0.8693 mL	1.7386 mL	4.3466 mL
	20 mM	0.1304 mL	0.6520 mL	1.3040 mL	3.2600 mL
	25 mM	0.1043 mL	0.5216 mL	1.0432 mL	2.6080 mL
	30 mM	0.0869 mL	0.4347 mL	0.8693 mL	2.1733 mL
	40 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6300 mL
	50 mM	0.0522 mL	0.2608 mL	0.5216 mL	1.3040 mL
	60 mM	0.0435 mL	0.2173 mL	0.4347 mL	1.0867 mL
	80 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	100 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6520 mL

Keywords

EPZ015666

22 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

EPZ015666

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) EPZ015666

Alle Histone Methyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

EPZ015666

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) EPZ015666

Alle Histone Methyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

EPZ015666 Related Classifications

HY-12727 Related Classifications